To identify new genetic factors for colorectal cancer (CRC), we conducted a genome-wide association study in east Asians. By analyzing genome-wide data in 2,098 cases and 5,749 controls, we selected 64 promising SNPs for replication in an independent set of samples, including up to 5,358 cases and 5,922 controls. We identified four SNPs with association P values of 8.58 × 10 −7 to 3.77 × 10 −10 in the combined analysis of all east Asian samples. Three of the four were replicated in a study conducted in 26,060 individuals of European descent, with combined P values of 1.22 × 10 −10 for rs647161 (5q31.1), 6.64 × 10 −9 for rs2423279 (20p12.3) and 3.06 × 10 −8 for rs10774214 (12p13.32 near the CCND2 gene), derived from meta-analysis of data from both east Asian and European-ancestry populations. This study identified three new CRC susceptibility loci and provides additional insight into the genetics and biology of CRC.
l e t t e r s between positive control samples, minor allele frequency (MAF) of <5% or P value for Hardy-Weinberg equilibrium of <1.0 × 10 −5 in controls for each study. Imputation was conducted for each study following the MaCH algorithm 18 using phased HapMap 2 Han Chinese in Beijing, China (CHB) and Japanese in Tokyo, Japan (JPT) samples as the reference. No apparent genetic admixture was detected, except for one sample from KCPS-II ( Supplementary Fig. 1 ). Associations between CRC risk and each of the genotyped and imputed SNPs were evaluated using logistic regression within each study after adjusting for age, sex and the first ten principal components using mach2dat 18 . Meta-analyses were conducted under a fixed-effects model using the METAL program 19 . There was little evidence for inflation in the association test statistics for any of the five studies (genomic inflation factor (λ) range of 1.02 to 1.04) or for all studies combined (λ = 1.01) ( Supplementary Fig. 2 and Supplementary Table 1 ). The observed number of SNPs with small P values was slightly larger than that expected by chance ( Supplementary Fig. 2) .
Multiple genomic locations were found that were potentially related to CRC risk (Supplementary Fig. 3 ). Nine SNPs identified from published GWAS conducted in populations of European ancestry showed associations with CRC risk at P < 0.05 in stage 1 (data not shown). To improve the statistical power for evaluating these SNPs, we genotyped 6,476 additional samples to bring the total sample size to 5,252 cases and 9,071 controls. Except for the 2 SNPs that are monomorphic in east Asians (rs6691170 and rs16892766), all 16 of the other SNPs identified from published GWAS conducted in European-ancestry populations showed association with CRC risk in the same direction as reported previously ( Supplementary Table 3 ). A significant association with CRC risk at P < 0.05 was found for 13 SNPs, including rs6687758, rs10936599, rs10505477, rs6983267, rs7014346, rs10795668, rs3802842, rs4444235, rs4779584, rs9929218, rs4939827, rs10411210 and rs961523. Except for two SNPs (rs6983267 and rs4779584), no statistically significant heterogeneity at P < 0.05 was observed between east Asian and European-ancestry populations ( Supplementary Table 3 ).
To identify new genetic factors for CRC, we selected 64 SNPs for replication in an independent set of 5,358 cases and 5,922 controls recruited in 5 studies conducted in China, Korea and Japan (Supplementary Table 2 ). SNPs were selected from among those that (i) had MAF of >5%; (ii) showed no heterogeneity across studies (P het > 0.05 and I 2 < 25%); (iii) were not in linkage disequilibrium (LD; r 2 < 0.2) with any known CRC risk variant reported from previous GWAS; (iv) had high imputation quality in each of the five studies (RSQ > 0.5); and (v) were associated at P < 0.01 in the combined analysis of all five studies included in stage 1. These criteria were used to prioritize SNPs for replication.
Of the 64 SNPs evaluated in stage 2, 7 showed association with CRC risk at P < 0.05 with a direction of association consistent with that observed in stage 1 ( Table 1 and Supplementary Table 4 ). In the combined analysis of data from stages 1 and 2, P values for associations with two SNPs (rs647161 at 5q31.1, odds ratio (OR) = 1.17, P = 3.77 × 10 −10 , and rs10774214 at 12p13.32, OR = 1.17, P = 5.48 × 10 −10 ) were lower than the conventional genome-wide significance level of 5.0 × 10 −8 , providing convincing evidence for an association of these SNPs with CRC risk ( Table 1 ). An additional SNP, rs2423279, showed a significant association in stage 2 after Bonferroni correction (corrected P < 7.8 × 10 −4 ) but did not reach the conventional GWAS significance level for association with CRC risk in the combined analysis of all samples (OR = 1.14, P = 2.29 × 10 −7 ). The association between CRC risk and each of these three SNPs was consistent across most studies ( Fig. 1) . Results for the other four SNPs that replicated in stage 2 at P < 0.05 (rs1665650, rs2850966, rs1580743 and rs4503064) are also presented ( Supplementary Table 4 ), including one SNP (rs1665650) with an association P value of 8.58 × 10 −7 in the combined analysis of all data from both stages ( Table 1) .
We next evaluated these top four SNPs ( Table 1) using data from GWAS in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and the Colon Cancer Family Registry (CCFR), which together include 11,870 cases and 14,190 controls of European ancestry 4, 20, 21 . Three of the four SNPs were replicated in the GECCO and CCFR sample, although the strength of the associations was weaker than in east Asians ( Table 2) . These results provide independent support of our findings in the east Asian population. Meta-analyses of data from both east Asian and European-ancestry populations provided strong evidence for associations of CRC risk with three SNPs, with P values all below the genome-wide significance threshold of 5 × 10 −8 ( Table 2) . The weaker associations observed in European-ancestry populations could be explained, in part, by differences in LD patterns at these loci for east npg l e t t e r s Asians and Europeans (Supplementary Fig. 4 ). It is possible that causal variants in these regions are tagged by different SNPs in these two populations or that there is allelic heterogeneity, in which different underlying causal variants exist in populations of Asian and European ancestry. The difference in LD structure between Asian and European descendants and possible allelic heterogeneity in these two populations might explain, in part, why these loci were not discovered in previous studies conducted in individuals of European ancestry. The fourth SNP evaluated in the GECCO and CCFR sample, rs1665650, however, was not replicated in individuals with European ancestry (OR = 0.96, P = 0.05). Stratification analyses showed that the association of CRC risk with each of the three replicated SNPs was generally consistent in Chinese, Korean and Japanese individuals (P het > 0.05), although the association with rs2423279 was not statistically significant in Japanese, perhaps owing to a small sample size (Supplementary Table 5 ). Associations of these three SNPs with CRC risk were similar for men and women (P het > 0.05) (Supplementary Table 6 ).
The rs10774214 SNP is located just 15 kb upstream of CCND2, the gene encoding cyclin D2 ( Fig. 2a) , a member of the D-type cyclin family, which also includes cyclins D1 and D3. These cyclins have a critical role in cell cycle control (from G1 to S phase) through activation of cyclin-dependent kinases (CDKs), primarily CDK4 and CDK6 (ref. 22) . CCND2 is closely related to CCND1, a well-established human oncogene 22, 23 . Although CCND2 has been less well studied than CCND1, several studies, including The Cancer Genome Atlas (TCGA), have shown that CCND2 is overexpressed in a substantial proportion of human colorectal tumors [22] [23] [24] [25] .
Overexpression of this cyclin may be an independent predictor of survival in individuals with CRC 24 . Several other genes, including PARP11, FGF23, FGF6, C12orf5 and RAD51AP1, are also in close proximity to the SNP identified in our study, of which both C12orf5 (also known as TIGAR, encoding TP53-induced glycolysis and apoptosis regulator) and RAD51AP1 were found to be overexpressed in CRC tissue included in TCGA 25 . rs10774214 is in strong LD with several SNPs that are located in potential transcription factor-binding sites, as determined using the TRANSFAC database 26 . Additional research may be warranted regarding possible mechanisms by which this SNP is related to CRC risk.
The rs647161 SNP is located on chromosome 5q31.1, where a cluster of SNPs were associated with CRC risk ( Fig. 2b) . Of the genes in this region (including PITX1, CATSPER3, PCBD2, MIR4461 and H2AFY), PITX1 is the closest to rs647161 (approximately 129 kb upstream). The PITX1 gene (encoding paired-like homeodomain 1) has been described as a tumor suppressor gene and may be involved in the tumorigenesis of multiple human cancers [27] [28] [29] [30] [31] , including CRC 27, 32 . PITX1 has been reported to suppress tumorigenicity by downregulating the RAS pathway, which is frequently altered in colorectal tumors 27 . Inhibition of PITX1 induces the RAS pathway and tumorigenicity, and restoring PITX1 in colon cancer cells inhibits tumorigenicity 27 . It also has been reported that PITX1 may activate TP53 (ref. 33 ) and regulate telomerase activity 34 . Consistent with its possible function as a tumor suppressor gene, PITX1 has been found to be downregulated in human cancer tissue samples and cell lines [27] [28] [29] [30] 32 . CRC tissue expressing wild-type KRAS showed significantly lower expression of PITX1 than tissue with mutant KRAS 32 . Most recently, low PITX1 expression was found to be associated with poor survival in individuals with CRC 35 . In addition, rs6596201, which is in moderate LD with rs647161 (r 2 = 0.25), is an expression quantitative trait locus (eQTL) (P = 2.42 × 10 −28 ) for the PITX1 gene 36 . Several other genes at this locus, including C5orf24, H2AFY and NEUROG1, were also found to be highly expressed in colorectal tumors included in TCGA (P < 0.001) 25 . Additional studies are warranted to explore a possible role for these genes in the etiology of CRC. npg l e t t e r s
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The rs2423279 SNP is located on chromosome 20p12.3, close to the HAO1 and PLCB1 genes (Fig. 2c) . HAO1 encodes hydroxyacid oxidase, which oxidizes 2-hydroxyacid. PLCB1 encodes phospholipase C-β1, which has an important role in the intracellular transduction of many extracellular signals. Overexpression of the PLCB1 gene has been observed in CRC tissue 25 . Possible mechanisms by which these genes are involved in CRC carcinogenesis are unknown. The rs2423279 SNP is 1,408,069 bp downstream of rs961253, a SNP previously identified in a European GWAS as being associated with CRC risk 10 . However, these two SNPs are not correlated in east Asians (r 2 = 0) or in Europeans (r 2 = 0). Adjustment for rs961253 did not change the results for rs2423279 (data not shown).
To our knowledge, this is the largest GWAS performed for CRC in east Asians, a population that differs from populations of European ancestry in CRC risk and certain aspects of genetic architecture. Results from our study, along with data from a large study conducted in a population of European ancestry, provide convincing evidence of associations with CRC risk for three new independent susceptibility loci at 5q31.1, 12p13.32 and 20p12.3. Results from this study provide new insights into the genetics and biology of CRC. 
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Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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Study populations. After quality control filtering, 7,456 cases and 11,671 controls from 10 studies were included in the consortium ( Supplementary  Table 2 ). Detailed descriptions of participating studies and demographic characteristics of study participants are provided in the Supplementary Note. Briefly, the consortium included 10,730 Chinese participants, 5,544 Korean participants and 2,853 Japanese participants. Chinese participants were from five studies: the Shanghai Study 1 (Shanghai-1, n = 3,102) , the Shanghai Study 2 (Shanghai-2, n = 485), the Guangzhou Study 1 (Guangzhou-1, n = 1,613) , the Guangzhou Study 2 (Guangzhou-2, n = 2,892) and the Guangzhou Study 3 (Guangzhou-3, n = 2,638). Korean participants were from three studies: the Korean Cancer Prevention Study-II (KCPS-II, n = 1,301), the Seoul Study (n = 1,522) and the Korea-National Cancer Center (Korea-NCC) Study (n = 2,721). Japanese participants were from two studies: the Aichi Study 1 (Aichi-1, n = 1,346) and the Aichi Study 2 (Aichi-2, n = 1,507). We also evaluated associations for the top 4 SNPs using data from 11,870 CRC cases and 14,190 controls of European ancestry included in GECCO and CCFR, which included 14 studies from the United States, Europe, Canada and Australia 4,20,21 .
Approval was granted from the relevant institutional review boards at all study sites, and all included participants gave informed consent.
Genotyping and quality control procedures. Detailed descriptions of genotyping and quality control procedures as well as design of plates and control samples are given in the Supplementary Note. Briefly, in stage 1, 481 cases and 2,632 controls from Shanghai-1 were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0 as described previously 14 . The average concordance percentage of quality control samples was 99.7%, with a median value of 100% in Shanghai-1 (refs. 14, 37, 38) . Stage 1 genotyping for 296 cases and 257 controls in Shanghai-2 was performed using Illumina HumanOmniExpress BeadChips. The same method was used to genotype cases from the Guangzhou-1 (n= 694) and Aichi-1 (n = 497) studies in stage 1. The positive quality control samples in these studies had an average concordance percentage of 99.41% and a median value of 99.97%. Cases and controls in KCPS-II were genotyped using the Affymetrix Genome-Wide Human SNP Array 5.0 (ref. 16) . Controls for the Guangzhou-1 and Aichi-1 studies were genotyped previously using the Illumina Human610-Quad BeadChip 15 and Illumina Infinium HumanHap610 BeadChip 17 platforms, respectively. Details of quality control procedures for these samples have been described previously [15] [16] [17] . We excluded from the analysis samples that were genetically identical or duplicated, had a genotype-determined sex that was inconsistent with self-reported data, had unclear population structure, had close relatives with a PI-HAT estimate greater than 0.25 or had a call rate of <95%. Within each study, SNPs were excluded if (i) MAF was <5%, (ii) the call rate was <95%; (iii) the genotyping concordance percentage was <95% in quality control samples; (iv) the P value for Hardy-Weinberg equilibrium was <1.0 × 10 −5 in controls; or (v) SNPs were not on the 22 autosomes. The final numbers of cases, controls and SNPs remaining for analysis in each participating study are presented in Supplementary Table 1 .
Genotyping for stage 2 was completed using the iPLEX Sequenom MassARRAY platform as described previously 14, 39 . With the exception of samples from the Guangzhou-3 study, which were genotyped at Fudan University (Shanghai), all other samples were genotyped at the Vanderbilt Molecular Epidemiology Laboratory. The average concordance percentage of the genotyping data for positive control samples was >99% with a median value of 100% for each of the five studies. SNPs were excluded from the analysis if (i) the call rate was <95%, (ii) the genotyping concordance percentage was <95% in control samples, (iii) there was an unclear genotype call or (iv) the P value for Hardy-Weinberg equilibrium was <7.8 × 10 −4 . The numbers of SNPs remaining for analysis in each participating study in stage 2 are presented in the Supplementary Note.
Genotyping for samples included in the GECCO and CCFR GWAS was conducted using Illumina BeadChip arrays, with the exception of the Ontario Familial Colorectal Cancer Registry study, for which Affymetrix arrays were used 4, 20, 21 . Details of the quality control procedures for these samples are presented in the Supplementary Note. SNP selection for replication. SNPs were selected for stage 2 replication if (i) data were available in each of the five stage 1 studies; (ii) MAF was >5% in each stage 1 study; (iii) no heterogeneity was detected across the five studies included in stage 1 (P het > 0.05 and I 2 < 25%); (iv) there was no LD (r 2 < 0.2) with any known risk variant reported from previous GWAS; (v) there was no LD (r 2 < 0.2) with the other SNPs identified in this study; (vi) there was high imputation quality in each of the five studies (RSQ > 0.5); and (vii) P < 0.01 in combined analysis of all stage 1 studies.
Evaluation of population structure. We evaluated population structure in each of the five participating studies included in stage 1 by using principalcomponents analysis (PCA). Genotyping data for uncorrelated genome-wide SNPs were pooled with data from HapMap to generate the first ten principal components using EIGENSTRAT software 40 (see URLs). The first two principal components for each sample were plotted using R (see URLs). We identified and excluded one participant of KCPS-II who was more than 6 s.d. away from the means of principal components 1 and 2 ( Supplementary  Fig. 1) . The remaining 7,847 samples showed clear east Asian origin, and these samples were included in the final genome-wide association analysis. Cases and controls in each of the five studies were in the same cluster as HapMap Asian samples. The estimated inflation factor λ ranged from 1.02 to 1.04 in these studies after adjusting for age, sex and the first ten principal components, with a λ of 1.01 for combined stage 1 data ( Supplementary Fig. 2 and Supplementary Table 1 ). Imputation. We used the MaCH 1.0 program 18 (see URLs) to impute genotypes for autosomal SNPs that were present in HapMap Phase 2 release 22 separately for each of the five studies included in stage 1. Genotype data from the 90 Asian subjects from HapMap were used as the reference. For Guangzhou-1 and Aichi-1, cases and controls were genotyped using different platforms. To improve imputation quality 41 , we identified SNPs for which data were available in both cases and controls (250,612 SNPs in Guangzhou-1 and 232,426 SNPs in Aichi-1) and used them to impute genotyping data. A total of 1,636,380 genotyped SNPs or imputed SNPs with high imputation quality (RSQ > 0.50) in all five studies were tested for association with CRC. To directly evaluate the imputation quality for the top four SNPs identified in our study, we genotyped them in approximately 2,500 samples included in stage 1. The agreement of genotype calls derived from direct genotyping and imputation was very high, with mean concordance rates of 98.05%, 95.61%, 99.84% and 97.90% for rs647161, rs10774214, rs2423279 and rs1665650, respectively ( Supplementary Table 7 ). Statistical analyses. Dosage data for genotyped and imputed SNPs for participants in each stage 1 study were analyzed using the program mach2dat 18 (see URLs). We coded 0, 1 or 2 copies of the effect allele as the dosage for genotyped SNPs, and, for imputed SNPs, we used the expected number of copies of the effect allele as the dosage score. This approach has been shown to give unbiased estimates in meta-analyses 42 . Associations between SNPs and CRC risk were assessed using ORs and 95% CIs derived from logistic regression models. ORs were estimated on the basis of the log-additive model and adjusted for age, sex and the first ten principal components. PLINK version 1.07 (see URLs) also was used to analyze genotype data 43 and yielded results virtually identical to those derived from dosage data using mach2dat 18 . Meta-analyses were performed using the inverse-variance method, assuming a fixed-effects model, and calculations were implemented in the METAL package 19 (see URLs).
Similar to stage 1, we used logistic regression models to derive ORs and 95% CIs for the 64 selected SNPs in stage 2, assuming a log-additive model with adjustment for age and sex. We performed joint analyses to generate summary results for combined samples from all studies, with additional adjustment for study site. We also conducted stratification analysis for the top four SNPs by population ancestry (Chinese, Korean or Japanese) and by sex. We used Cochran's Q statistic to test for heterogeneity 44 and the I 2 statistic to quantify heterogeneity 45 across studies as described elsewhere in detail 46 . Analyses for stage 2, as well as combined stage 1 and 2 data, were conducted using SAS, version 9.2 (see URLs), with the use of two-tailed tests. P values of <5×10 −8 in the combined analysis was considered statistically significant.
We used Haploview version 4.2 (see URLs; ref. 47) to generate a genomewide Manhattan plot for results from the stage 1 meta-analysis. Forest plots
